Ladenburg Thalmann Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Anixa Biosciences (NASDAQ:ANIX) stock moved upwards by 9.1% to $3.35 during Tuesday's after-market session. The company's market cap stands at $100.9 million.
61 Biggest Movers From Yesterday
Gainers
Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.
Palisade Bio Reports Granted New US Patent Covering Protease Inhibitor LB1148 For Treating Adhesions, Postoperative Ileus
Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio
The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from Phase 2 Trial